Grifols introduces the AlphaKit® QuickScreen, a novel point-of-care screening device to detect alpha1-antitrypsin (AAT)

Grifols introduces the AlphaKit® QuickScreen, a novel point-of-care screening
   device to detect alpha1-antitrypsin (AAT) deficiency, a leading cause of
                      genetic emphysema / COPD in adults

  PR Newswire

  BARCELONA, Spain, Sept. 9, 2013

-- Details presented at the annual congress of the European Respiratory
Society (ERS)

BARCELONA, Spain, Sept. 9, 2013 /PRNewswire/ -- Grifols, a global healthcare
company based in Barcelona, Spain, today introduced the AlphaKit ^®
QuickScreen, a novel and efficient point-of-care device that can be used by
physicians to screen for alpha [1] -antitrypsin (AAT) deficiency, a rare,
life-threatening condition. The AlphaKit ^® QuickScreen is in late stage
development and is anticipated to be available for use in several European
countries in early 2014. The AlphaKit ^® QuickScreen was presented as part of
the Grifols symposium "Alpha [1] -Antitrypsin Deficiency: Honoring the Past
and Embracing the Future."

(Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO )

The AlphaKit ^® QuickScreen, as the name implies, is a quick way for
physicians and healthcare providers to screen COPD and emphysema patients for
a unique genetic mutation commonly associated with AAT deficiency. Requiring
only a few drops of blood, the AlphaKit ^® QuickScreen is able to detect the
presence of the Z protein that is responsible for over 95% of severe AAT
deficiency cases within 15 minutes.

Individuals suffering from AAT deficiency often develop COPD, leading to
disability and premature death. AAT deficiency is estimated to affect over
100,000 people in Europe alone, although greater than 90% of individuals
remain undiagnosed.

"The good news is that for most patients, AAT deficiency can quickly be ruled
out during a medical exam – and it only needs to be done once in a patient's
life. If a patient tests positive, they are either a carrier of this genetic
condition or are at risk of developing AAT deficiency emphysema," says Dr.
Claus Vogelmeier, Professor of Internal and Respiratory Medicine at the
Hospital of the Universities of Giessen and Marburg, Germany. "Thus, we can
proceed with a full diagnostic test to make the definitive diagnosis as we've
always done and if appropriate, begin augmentation therapy."

Grifols anticipates that the AlphaKit ^® QuickScreen will lead to improved
patient outcomes by reducing the time and number of physicians it takes to
make an accurate and timely diagnosis. "It typically takes seven years and
more than four physicians before the AAT deficiency diagnosis is made," says
Dr. Marc Miravitlles, Chest Physician and Senior Researcher, Department of
Pulmonology at the Hospital Vall d'Hebron, Barcelona, Spain. "By this point,
the patients are symptomatic, and it is apparent that they may not have normal
or usual COPD." 

Grifols currently provides a definitive and accurate diagnostic test, known as
the AlphaKit ^® to physicians in several countries. The AlphaKit ^® has also
been used to screen at-risk patients, and results are received in
approximately two weeks. Grifols will continue to offer both the screening
device and the diagnostic test, as they complement each other and facilitate
detection of AAT deficiency. An early diagnosis allows patients to make
informed decisions and provides the opportunity to make lifestyle changes that
can add years to their lives.

About Grifols Grifols is a global healthcare company with a 70-year legacy of
improving people's health and well-being through the development of
life-saving plasma medicines, hospital pharmacy products, and diagnostic
technology for clinical use.

As a leading producer of plasma medicines, Grifols has a presence in more than
100 countries and is the world leader in plasma collection, with 150 plasma
donation centres across the US. Grifols is committed to increasing patient
access to its life-saving plasma medicines through significant manufacturing
expansions and the development of new therapeutic applications of plasma
proteins. The company is headquartered in Barcelona, Spain, and employs more
than 11,000 people worldwide.

In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A
shares are listed on the Spanish Stock Exchange, where they form part of the
Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado
Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS). For more
information visit www.grifols.com .

About Alpha [1] -Antitrypsin Deficiency Alpha [1] -antitrypsin deficiency,
also known as AAT deficiency or alpha [1] , is an inherited disorder that
causes a significant reduction in the naturally occurring protein, alpha [1]
-proteinase inhibitor. While rare, alpha [1] is the most common cause of
genetic emphysema in adults and the most common cause of liver disease in
children. Individuals suffering from alpha [1] often develop severe chronic
obstructive pulmonary disease (COPD) leading to disability and premature
death. Alpha [1] is estimated to affect 100,000 people in Europe alone,
although greater than 90% of individuals remain undiagnosed.



Website: http://www.grifols.com
Contact: Europe Media Contact / Grifols Global Press Office, Raquel Lumbreras,
raquel_lumbreras@duomocomunicacion.com; Borja Gomez,
borja_gomez@duomocomunicacion.com, +34-91-311-92-89